Date: 2015-09-09
Type of information: Licensing agreement
Compound: lipoprotein signal peptidase (“Lsp”) inhibitors
Company: Opko Health (USA - Fl) The Scripps Research Institute (USA - CA)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
Disease: infectious diseases
Details: * On September 9, 2015, OPKO Health announced a global license agreement with The Scripps Research Institute (TSRI) for the development and commercialization of novel lipoprotein signal peptidase (“Lsp”) inhibitors developed and discovered using a proprietary high throughput screening technology funded and exclusively licensed by OPKO from TSRI. “This technology is one of the best opportunities we have for the development of specific inhibitors of Lsp, which represents a remarkable target for the development of broad and novel antimicrobial agents, as it is highly conserved throughout the bacterial and mycoplasma kingdoms and no human homologues exist,” said TSRI Professor Dennis Wolan, Ph.D., who led the research on this screening platform. OPKO has agreed to fund additional work in Dr. Wolan’s laboratory at TSRI and to move as rapidly as possible into clinical trials.
Financial terms:
Latest news:
